Amylyx soars as blood sugar drug succeeds in late-stage trial

Amylyx Pharmaceuticals

18/08/2026 12:39

** Shares of drug developer Amylyx Pharmaceuticals AMLX.O  rise 42% to $30.45 premarket
** Co says its drug avexitide met the main goal of improving post-bariatric hypoglycemia in a late-stage trial
** The condition is marked by dangerously low blood sugar levels in patients who have undergone weight-loss surgery
** In the 78-patient trial, the drug achieved a 55% reduction in these low blood sugar episodes compared with a placebo during the 16-week study
** Co plans to submit the drug for U.S. regulatory approval by the end of this year, aiming for a potential commercial launch in 2027
** Up to last close, stock up 77.4% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))